Aktis Oncology, Inc. (AKTS) vs PROCEPT BioRobotics Corporation (PRCT)
A side-by-side comparison of Aktis Oncology, Inc. and PROCEPT BioRobotics Corporation across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
AKTS
Aktis Oncology, Inc.
$18.28HealthcareDelayed quote: Oct 6, 2026, 12:55 PM EDT
PRCT
PROCEPT BioRobotics Corporation
$17.41HealthcareDelayed quote: Oct 6, 2026, 12:50 PM EDT
Total return — AKTS vs PRCT
growth of $100 · dividends reinvested · last 1yAKTS -17.3% (-17.3%/yr)PRCT -45.7% (-45.7%/yr)AKTS compounded faster over this window
AKTS PRCT
AKTS vs PRCT: by the numbers
- •PRCT is the larger company ($991M vs $976M market cap).
- •Both run net losses; PRCT's is the smaller (-32.54% vs -727.04% net margin).
Metrics side by side
Valuation
| Metric | AKTS | PRCT |
|---|---|---|
| P/S ratio | 97.05 | 2.94 |
| P/B ratio | 2.01 | 2.91 |
Profitability
| Metric | AKTS | PRCT |
|---|---|---|
| Gross margin | 100.00% | 63.74% |
| Operating margin | -1149.52% | -33.86% |
| Net margin | -727.04% | -32.54% |
| ROE | -15.09% | -32.27% |
| ROIC | -16.54% | -27.51% |
Growth (annualized)
| Metric | AKTS | PRCT |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 74.27% |
| Total return CAGR (5Y) | N/A | -14.36% |
Go deeper
Dig into the metrics
Aktis Oncology ROEPROCEPT BioRobotics ROEAktis Oncology operating marginPROCEPT BioRobotics operating marginAktis Oncology revenue growthPROCEPT BioRobotics revenue growthAktis Oncology free cash flowPROCEPT BioRobotics free cash flow
Aktis Oncology & PROCEPT BioRobotics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.